

Blood endocan as a biomarker for breast cancer recurrence

Kentaro Daiki¹, Yoko Kanada², Aya Nagata³, Kanae Taruno⁴, Katsuhide Igarashi⁵,
Toshiko Yamochi⁶, Hirotaka Ota⁶, Fumiaki Sato¹, Seigo Nakamura^{4,*}, Yoshinori Kato^{1,*}

¹ Laboratory for Bioanalysis and Onco-Pharmaceutics, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan;

² Department of Breast Surgical Oncology, Tokyo Rosai Hospital, 4-13-21 Ohmori-Minami, Ohta-ku, Tokyo, Japan;

³ Department of Breast Surgical Oncology, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama-shi, Kanagawa, Japan;

⁴ Division of Breast Surgical Oncology, Department of Surgery, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan;

⁵ Laboratory of Biofunctional Science, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan;

⁶ Department of Pathology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan.

Corresponding authors:

* Seigo Nakamura, M.D., Ph.D.

Phone: +81-3-3784-8707; E-mail: seigonak@med.showa-u.ac.jp

* Yoshinori Kato, Ph.D.

Phone: +81-3-5498-5844; E-mail: y-kato@hoshi.ac.jp

Supplementary Information

Supplementary Figures




Figure S1 Pathological assessment of endocan expression in primary breast tumors removed by the surgery. **a**, Representative tissue section from a breast cancer patient who showed blood endocan levels below the cutoff value (1.68 ng/mL). **b**, Representative tissue section from a breast cancer patient who tested positive for endocan by the blood test.




Figure S2 Difference in *ESM1* expression of MDA-MB-231BR/*mVenus-Akaluc* obtained by limiting dilution cloning. Total RNA was extracted from twelve clones and bulk cells, and the expressions of the *ESM1* and *RPS18* were quantitated in real-time PCR. Each primer used in this study was as follows: *ESM1*-FW (5'-TTG CTA CCG CAC AGT CTC AG-3'), *ESM1*-RV (5'-GTG CCG TAG GGA CAG TCT TT-3'), *RPS18*-FW (5'-ATA CAG CCA GGT CCT AGC CA-3'), *RPS18*-RV (5'-AAG TGA CGC AGC CCT CTA TG-3').

Supplementary Tables

Table S1 Clinical characteristics of breast cancer patients whose blood was collected before and after the surgery.

Clinicopathological features	Total patients, N (N = 16)	Endocan negative population, N (%) (N = 8)	Endocan positive population, N (%) (N = 8)
<u>Age at blood collection</u>			
Median (years)	53	52	52
(Minimum-Maximum)	(42-83)	(46-83)	(42-76)
<u>Menopausal status</u>			
Pre-menopausal	9	4 (44.4%)	5 (55.6%)
Post-menopausal	7	4 (57.1%)	3 (42.9%)
<u>BMI</u>			
BMI<25%	12	6 (50.0%)	6 (50.0%)
BMI \geq 25%	4	2 (50.0%)	2 (50.0%)
<u>ER expression</u>			
<90%	0		
\geq 90%	16	8 (50.0%)	8 (50.0%)
<u>PgR expression</u>			
<10%	2	1 (50.0%)	1 (50.0%)
10% \leq PgR <90%	4	2 (50.0%)	2 (50.0%)
\geq 90%	10	5 (50.0%)	5 (50.0%)
<u>Tumor size</u>			
Tis*	1	1 (100.0%)	0 (0.0%)
T1	9	5 (55.6%)	4 (44.4%)
T2	6	2 (33.3%)	4 (66.7%)
<u>Lymph node metastasis</u>			
N-	11	6 (54.5%)	5 (45.5%)
N+	5	2 (40.0%)	3 (60.0%)
<u>Pathological Stage</u>			
0	1	1 (100.0%)	0 (0.0%)
I	7	4 (57.1%)	3 (42.9%)
II	8	3 (37.5%)	5 (62.5%)
<u>Ki67 labeling index</u>			
<20%	11	6 (54.5%)	5 (45.5%)
\geq 20%	4	2 (50.0%)	2 (50.0%)
Unknown	1	0 (0.0%)	1 (100.0%)

* Tis: Ductal carcinoma in situ (DCIS) or Paget's disease with no associated tumor mass.

Table S2 Clinical characteristics of breast cancer patients with postoperative recurrence.

Clinicopathological features	Total patients, <i>N</i> (<i>N</i> = 20)	Endocan negative population, <i>N</i> (%) (<i>N</i> = 7)	Endocan positive population, <i>N</i> (%) (<i>N</i> = 13)
<u>Age at blood collection</u>			
Median (years)	55	63	55
(Minimum-Maximum)	(35-78)	(35-78)	(41-70)
<u>ER expression</u>			
<90%	9	3 (33.3%)	6 (66.7%)
≥90%	11	4 (36.4%)	7 (63.6%)
<u>PgR expression</u>			
<10%	11	4 (36.4%)	7 (63.6%)
10% ≤ PgR <90%	5	1 (20.0%)	4 (80.0%)
≥90%	4	2 (50.0%)	2 (50.0%)
<u>HER2 expression</u>			
≤1+	16	7 (43.8%)	9 (56.3%)
2+	3	0 (0.0%)	3 (100.0%)
≥3+	1	0 (0.0%)	1 (100.0%)
<u>Subtype</u>			
Luminal	12	5 (41.7%)	7 (58.3%)
HER2	1	0 (0.0%)	1 (100.0%)
Triple-negative	7	2 (28.6%)	5 (71.4%)
<u>Ki67 labeling index</u>			
<20%	6	2 (33.3%)	4 (66.7%)
≥20%	14	5 (35.7%)	9 (64.3%)

Table S3 Effect of the interval between the surgery and the blood collection on changes in blood endocan levels.

Patient #	Pre-surgical endocan level (ng/mL)	Post-surgical endocan level (ng/mL)	UP or DOWN	Interval of time between the surgery and the blood collection (Days)
1	5.97	10.90	UP	29
2	5.66	1.03	DOWN	32
3	12.45	1.47	DOWN	32
4	17.31	5.60	DOWN	46
5	5.60	4.38	DOWN	59
6	4.41	2.20	DOWN	64
7	2.24	14.51	UP	67
8	19.64	10.86	DOWN	83

Table S4 Endocan, CEA, and CA15-3 concentrations in the blood samples of patients with postoperative breast cancer recurrence.

Patient #	Endocan level (ng/mL)	CEA level (ng/mL)	CA15-3 level (U/mL)
1	<0.156	5.6	23.9
2	0.16	2.8	12.4
3	0.30	4.8	8.1
4	0.43	3.1	85.9
5	0.61	4.6	17.4
6	0.89	2.7	14.6
7	1.22	1.5	14.2
8	2.35	9.4	189.9
9	3.88	1.7	5.8
10	4.48	0.9	5.5
11	5.20	1.4	25.6
12	5.78	0.6	18.1
13	5.80	1.3	4.6
14	6.21	23.9	8.6
15	6.63	1.7	27.2
16	9.13	10.2	95.7
17	9.45	6.4	30.2
18	10.34	2.1	6.5
19	10.75	23.4	34.7
20	10.82	4.1	9.0

Red numbers indicate positive for the respective biomarker.